These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1385 related articles for article (PubMed ID: 27433846)

  • 81. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.
    Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA
    Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Germline DNA-Repair Genes and HOXB13 Mutations in Korean Men with Metastatic Prostate Cancer: Data from a Large Korean Cohort.
    Song SH; Kim HM; Jung YJ; Kook HR; Jeon S; Bhak J; Kim JH; Lee H; Oh JJ; Lee S; Hong SK; Byun SS
    World J Mens Health; 2023 Oct; 41(4):960-968. PubMed ID: 37118955
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Germline Variants in DNA Damage Repair Genes and
    Trendowski MR; Sample C; Baird T; Sadeghpour A; Moon D; Ruterbusch JJ; Beebe-Dimmer JL; Cooney KA
    JCO Precis Oncol; 2022 Nov; 6():e2200460. PubMed ID: 36446039
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
    Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
    [No Abstract]   [Full Text] [Related]  

  • 86. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer.
    Goldstein JB; Zhao L; Wang X; Ghelman Y; Overman MJ; Javle MM; Shroff RT; Varadhachary GR; Wolff RA; McAllister F; Futreal A; Fogelman DR
    Clin Cancer Res; 2020 Mar; 26(6):1385-1394. PubMed ID: 31871297
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
    Hu C; Hart SN; Polley EC; Gnanaolivu R; Shimelis H; Lee KY; Lilyquist J; Na J; Moore R; Antwi SO; Bamlet WR; Chaffee KG; DiCarlo J; Wu Z; Samara R; Kasi PM; McWilliams RR; Petersen GM; Couch FJ
    JAMA; 2018 Jun; 319(23):2401-2409. PubMed ID: 29922827
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
    Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
    PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer.
    Ramamurthy C; Stutz EW; Goros M; Gelfond J; Johnson-Pais TL; Thompson IM; Leach RJ; Liss MA
    Clin Genitourin Cancer; 2022 Jun; 20(3):237-243. PubMed ID: 35260348
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The role of BRCA1 and BRCA2 in prostate cancer.
    Castro E; Eeles R
    Asian J Androl; 2012 May; 14(3):409-14. PubMed ID: 22522501
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
    Yadav S; Hart SN; Hu C; Hillman D; Lee KY; Gnanaolivu R; Na J; Polley EC; Couch FJ; Kohli M
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923857
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.
    Schroeck FR; Zuhlke KA; Siddiqui J; Siddiqui R; Cooney KA; Wei JT
    J Urol; 2013 Mar; 189(3):849-53. PubMed ID: 23036981
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
    J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Disparities in germline testing among racial minorities with prostate cancer.
    Weise N; Shaya J; Javier-Desloges J; Cheng HH; Madlensky L; McKay RR
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):403-410. PubMed ID: 34775478
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.
    Vlaming M; Bleiker EMA; van Oort IM; Kiemeney LALM; Ausems MGEM
    BMC Cancer; 2022 Dec; 22(1):1365. PubMed ID: 36581909
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    Paller CJ; Antonarakis ES; Beer TM; Borno HT; Carlo MI; George DJ; Graff JN; Gupta S; Heath EI; Higano CS; McKay RR; Morgans AK; Patnaik A; Petrylak DP; Rettig MB; Ryan CJ; Taplin ME; Whang YE; Vinson J; Cheng HH; Giri VN;
    Clin Genitourin Cancer; 2019 Aug; 17(4):275-282.e1. PubMed ID: 31171481
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.
    Giri VN; Obeid E; Gross L; Bealin L; Hyatt C; Hegarty SE; Montgomery S; Forman A; Bingler R; Kelly WK; Dicker AP; Winheld S; Trabulsi EJ; Chen DYT; Lallas CD; Allen BA; Daly MB; Gomella LG
    JCO Precis Oncol; 2017 May; 1():. PubMed ID: 34164591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.